The expression of PD-L1 in tissue does not seem to be a good biomarker in metastatic melanoma treated with targeted therapy [31], although its expression does increase in the microenvironment after the inhibition of BRAF, both in preclinical models and in tumour biopsies [32,33]. This evidence concerns the gene BRAF and neoplasm.